» Articles » PMID: 26840477

THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a Review

Overview
Specialty Gastroenterology
Date 2016 Feb 4
PMID 26840477
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Irritable bowel syndrome is a common, chronic relapsing gastrointestinal disorder that affects 7%-22% of the population worldwide. According to Rome III Criteria, the disorder is defined by the coexistence of abdominal discomfort or pain associated with an alteration in bowel habits. Its pathophysiology is not completely understood but, in addition to some important abnormalities, the disturbed intestinal microbiota has also been described supported by several strands of evidence. The treatment of irritable bowel syndrome is based upon several therapeutic approaches but few have been successful or without adverse events and more recently the gut microbiota and the use of probiotics have emerged as a factor to be considered. Probiotics are live micro-organisms which when consumed in adequate amounts confer a health benefit to the host, such as Lactic bacteria among others. An important scientific rationale has emerged for the use of probiotics in irritable bowel syndrome, although the data regarding different species are still limited. Not all probiotics are beneficial: it is important to select the specific strain which should be supported by good evidence base. The mechanisms of action of probiotics are described and the main strains are quoted.

Citing Articles

Comparing lactic acid bacteria biodiversity in irritable bowel syndrome and healthy gut microbiota.

Azimi A, Yavarmanesh M, Gholamin M Food Sci Nutr. 2024; 12(11):9212-9226.

PMID: 39619992 PMC: 11606828. DOI: 10.1002/fsn3.4477.


How can probiotic improve irritable bowel syndrome symptoms?.

Benjak Horvat I, Gobin I, Kresovic A, Hauser G World J Gastrointest Surg. 2021; 13(9):923-940.

PMID: 34621470 PMC: 8462084. DOI: 10.4240/wjgs.v13.i9.923.


Modulating effects of the probiotic on the hepatic fibrotic process induced by CCl in Wistar rats.

Delgado-Venegas C, Martinez-Hernandez S, Cervantes-Garcia D, Montes de Oca-Luna R, Loera-Arias M, Mata-Martinez M Exp Ther Med. 2021; 21(4):339.

PMID: 33732312 PMC: 7903445. DOI: 10.3892/etm.2021.9770.


Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis.

Luo M, Zhuang X, Tian Z, Xiong L BMC Gastroenterol. 2021; 21(1):14.

PMID: 33407171 PMC: 7788881. DOI: 10.1186/s12876-020-01577-5.


Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review).

Barboi O, Ciortescu I, Chirila I, Anton C, Drug V Exp Ther Med. 2020; 20(6):185.

PMID: 33101475 PMC: 7579772. DOI: 10.3892/etm.2020.9315.